BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND RAD51B, ENSG00000182185, 5890, RAD51L1, O15315, hREC2, R51H2, REC2, MGC34245
35 results:

  • 1. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
    Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Structure and function of the rad51b-RAD51C-RAD51D-XRCC2 tumour suppressor.
    Greenhough LA; Liang CC; Belan O; Kunzelmann S; Maslen S; Rodrigo-Brenni MC; Anand R; Skehel M; Boulton SJ; West SC
    Nature; 2023 Jul; 619(7970):650-657. PubMed ID: 37344587
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Hu C; Nagaraj AB; Shimelis H; Montalban G; Lee KY; Huang H; Lumby CA; Na J; Susswein LR; Roberts ME; Marshall ML; Hiraki S; LaDuca H; Chao E; Yussuf A; Pesaran T; Neuhausen SL; Haiman CA; Kraft P; Lindstrom S; Palmer JR; Teras LR; Vachon CM; Yao S; Ong I; Nathanson KL; Weitzel JN; Boddicker N; Gnanaolivu R; Polley EC; Mer G; Cui G; Karam R; Richardson ME; Domchek SM; Yadav S; Hruska KS; Dolinsky J; Weroha SJ; Hart SN; Simard J; Masson JY; Pang YP; Couch FJ
    Cancer Res; 2023 Aug; 83(15):2557-2571. PubMed ID: 37253112
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V
    Cell Death Dis; 2022 Oct; 13(10):909. PubMed ID: 36307400
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Homologous recombination-deficient mutation cluster in tumor suppressor
    Prakash R; Rawal Y; Sullivan MR; Grundy MK; Bret H; Mihalevic MJ; Rein HL; Baird JM; Darrah K; Zhang F; Wang R; Traina TA; Radke MR; Kaufmann SH; Swisher EM; Guérois R; Modesti M; Sung P; Jasin M; Bernstein KA
    Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2202727119. PubMed ID: 36099300
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
    BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A truncating variant of rad51b associated with primary ovarian insufficiency provides insights into its meiotic and somatic functions.
    Franca MM; Condezo YB; Elzaiat M; Felipe-Medina N; Sánchez-Sáez F; Muñoz S; Sainz-Urruela R; Martín-Hervás MR; García-Valiente R; Sánchez-Martín MA; Astudillo A; Mendez J; Llano E; Veitia RA; Mendonca BB; Pendás AM
    Cell Death Differ; 2022 Dec; 29(12):2347-2361. PubMed ID: 35624308
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
    Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Homologous Recombination Deficiency: cancer Predispositions and Treatment Implications.
    Toh M; Ngeow J
    Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition.
    Cavaillé M; Uhrhammer N; Privat M; Ponelle-Chachuat F; Gay-Bellile M; Lepage M; Molnar I; Viala S; Bidet Y; Bignon YJ
    Genes Chromosomes Cancer; 2021 Feb; 60(2):73-78. PubMed ID: 33099839
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for ovarian cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and ovarian cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort.
    Gao XR; Huang H; Kim H
    Hum Mol Genet; 2019 Apr; 28(7):1162-1172. PubMed ID: 30535121
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [The French Genetic and cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis.
    Zeng X; Zhang Y; Yang L; Xu H; Zhang T; An R; Zhu K
    Medicine (Baltimore); 2018 Jun; 97(26):e11251. PubMed ID: 29952992
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
    Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
    Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. rad51b in Familial Breast cancer.
    Pelttari LM; Khan S; Vuorela M; Kiiski JI; Vilske S; Nevanlinna V; Ranta S; Schleutker J; Winqvist R; Kallioniemi A; Dörk T; Bogdanova NV; Figueroa J; Pharoah PD; Schmidt MK; Dunning AM; García-Closas M; Bolla MK; Dennis J; Michailidou K; Wang Q; Hopper JL; Southey MC; Rosenberg EH; Fasching PA; Beckmann MW; Peto J; Dos-Santos-Silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Surowy H; Guénel P; Truong T; Bojesen SE; Nordestgaard BG; Benitez J; González-Neira A; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Brüning T; Lindblom A; Margolin S; Mannermaa A; Hartikainen JM; Chenevix-Trench G; ; Van Dyck L; Janssen H; Chang-Claude J; Rudolph A; Radice P; Peterlongo P; Hallberg E; Olson JE; Giles GG; Milne RL; Haiman CA; Schumacher F; Simard J; Dumont M; Kristensen V; Borresen-Dale AL; Zheng W; Beeghly-Fadiel A; Grip M; Andrulis IL; Glendon G; Devilee P; Seynaeve C; Hooning MJ; Collée M; Cox A; Cross SS; Shah M; Luben RN; Hamann U; Torres D; Jakubowska A; Lubinski J; Couch FJ; Yannoukakos D; Orr N; Swerdlow A; Darabi H; Li J; Czene K; Hall P; Easton DF; Mattson J; Blomqvist C; Aittomäki K; Nevanlinna H
    PLoS One; 2016; 11(5):e0153788. PubMed ID: 27149063
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.